Assembly biosciences reports interim phase 1b results from clinical trial evaluating next-generation capsid assembly modulator candidate abi-4334 in chronic hepatitis b

– abi-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –

ASMB Ratings Summary

ASMB Quant Ranking